KCKadin T. Crosby

Kadin T. Crosby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kadin T. Crosby has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Publisher Correction: Targeting cancer-specific mutations with RNA-triggered chromatin shredding

    by Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T. Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia, et al.

  • Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding

    by Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, Zhaojun Wang, Jared Thompson, Kadin T. Crosby, Hesong Han, Arushi Singhal, Wayne Ngo, Chenglong Xia, et al.

    Genetic mutations that drive cancer often occur in tumor suppressor proteins, including the p53 transcription factor which is altered in ~40-50% of cases1,2. However, current therapies fail to target most such mutations because the mutant proteins typically lack defined drug-binding pockets, and restoring the endogenous function has proven challenging. Here, we programmed CRISPR-Cas12a2, an RNA-guided nuclease with trans-nucleolytic cleavage activities3,4, to selectively kill cancer cells by targeting cancer-specific transcripts. This approach limits cell growth by inducing trans shredding of chromatin, triggering DNA damage responses and cell death. Unlike existing methods, RNA-guided Cas12a2 senses cellular RNA signatures, enabling precise targeting of undruggable mutations. Transcript-activated chromatin shredding provides a new approach to precision disease treatments for undruggable targets.


  • Open Access

    RNA-triggered cell killing with CRISPR–Cas12a2

    by Paul Scholz, Jared Thompson, Kadin T. Crosby, Torsten Fauth, Nathan M. Krah, Grant Schlauderaff, Robin Back, Zachary A. Berkheimer, Alivia Jolley, Dirk Sombroek, et al.

    Selectively eradicating target cells on the basis of their genetic or transcriptional identity remains important in basic research, medicine, biotechnology and agriculture1,2,3. For applications involving bacteria, CRISPR nucleases offer promising options due to their ability to enact RNA-guided counterselection4,5,6,7; however, using these same nucleases for counterselection in eukaryotes has proven much more restrictive8,9,10,11,12,13,14. Here we show that Cas12a2, a recently discovered type V CRISPR nuclease, exhibits RNA-triggered DNA shredding15,16, and enables programmable and sequence-specific elimination of yeast and human cells expressing a target transcript. Triggering Cas12a2 elicits rampant double-stranded DNA breaks in trans, leading to cell death. Cell killing can be activated by a wide range of target transcripts, with no observed off-target activation. Leveraging this approach, we selectively eliminate cells that harbour human papillomavirus, cells that failed to undergo gene editing, or cells that encode a prevalent oncogenic point mutation in KRAS. These findings expand the CRISPR toolbox to allow the selective elimination of eukaryotic cells on the basis of their transcriptional profile.


  • Top Cited Papers
    Open Access

    RNA-triggered Cas12a3 cleaves tRNA tails to execute bacterial immunity

    by Oleg Dmytrenko, Biao Yuan, Kadin T. Crosby, Max Krebel, Xiye Chen, Jakub S. Nowak, Andrzej Chramiec-Głąbik, Bamidele Filani, Anne-Sophie Gribling-Burrer, Wiep van der Toorn, et al.

    In all domains of life, tRNAs mediate the transfer of genetic information from mRNAs to proteins. As their depletion suppresses translation and, consequently, viral replication, tRNAs represent long-standing and increasingly recognized targets of innate immunity 1–5 . Here we report Cas12a3 effector nucleases from type V CRISPR–Cas adaptive immune systems in bacteria that preferentially cleave tRNAs after recognition of target RNA. Cas12a3 orthologues belong to one of two previously unreported nuclease clades that exhibit RNA-mediated cleavage of non-target RNA, and are distinct from all other known type V systems. Through cell-based and biochemical assays and direct RNA sequencing, we demonstrate that recognition of a complementary target RNA by the CRISPR RNA triggers Cas12a3 to cleave the conserved 5′-CCA-3′ tail of diverse tRNAs to drive growth arrest and anti-phage defence. Cryogenic electron microscopy structures further revealed a distinct tRNA-loading domain that positions the tRNA tail in the RuvC active site of the nuclease. By designing synthetic reporters that mimic the tRNA acceptor stem and tail, we expanded the capacity of current CRISPR-based diagnostics for multiplexed RNA detection. Overall, these findings reveal widespread tRNA inactivation as a previously unrecognized CRISPR-based immune strategy that broadens the application space of the existing CRISPR toolbox.